Tegaserod, a 5-ht4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 10, 2001, Pages 1655-1666

  Muller Lissner S A ^a   Fumagalli, I ^b   Bardhan, K D ^c   Pace, F ^d   Pecher, E ^e   Nault, B ^e   Ruegg P ^e  

^a Park Klinik Weissensee   (Germany)

^b Private Practice   (Switzerland)

^c ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MILAN   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 0034794595     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01094.x     Document Type: Article

References (39)

1. Functional bowel disorders and functional abdominal pain
2. Review article: Irritable bowel syndrome
3. Irritable bowel syndrome in office-based practice in the United States
4. Impact of irritable bowel syndrome on quality of life and resource use in the United States and the United Kingdom
5. Impact of irritable bowel syndrome on quality of life
6. Economic burden of irritable bowel syndrome: Proposed strategies to control expenditures
7. Irritable bowel syndrome: New pharmaceutical approaches to treatment
8. Symptom differences in moderate to severe IBS patients, based on predominant bowel habit
9. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception
10. Irritable bowel syndrome: Review and a graduated multicomponent treatment approach
11. 4 receptors: An update
12. 4 receptors
13. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
14. 4 receptor agonist
15. 4 receptor partial agonist, on colorectal distension in rats
16. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists
17. The properties of a new prokinetically active drug, SDZ HTF 919
18. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
19. 4 receptor agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptying
20. 4 receptor agonist, in a model of slow colonic transit
21. 4 receptor agonist tegaserod (HTF 919) accelerates upper and lower gastrointestinal (GI) transit
22. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
23. Functional bowel disease and functional abdominal pain
24. Validation of a global relief measure in clinical trials of irritable bowel syndrome with tegaserod
25. The irritable bowel syndrome: Toward optimal design of controlled treatment trials
26. Design of treatment trials for functional gastrointestinal disorders
27. Irritable bowel syndrome clinical trial design: Future needs
28. Controlled treatment trials in the irritable bowel syndrome: A critique
29. Problems and challenges in the design of irritable bowel syndrome clinical trials: Experience from published trials
30. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone
31. Colonic motility in humans: A growing understanding
32. Principles of applied neurogastroenterology: Physiology/motility-sensation
33. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in intestinal motility disorders
34. Treatment of chronic constipation with cisapride and placebo
35. 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome: A placebo-controlled study of cisapride
36. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
37. Functional bowel disorders and functional abdominal pain
38. Long QT syndrome during high-dose cisapride
39. Cisapride-induced prolongation of cardiac action potential and early after depolarizations in rabbit Purkinje fibres